Silver Spring, MD – The fight against the opioid epidemic in the United States took a major step forward. For the first time ever, the Food and Drug Administration requested that an opioid should be removed from the marketplace.

The FDA formally asked Endo, a pharmaceutical company, to stop selling Opana ER, an extended-release form of the opioid drug oxymorphone. The FDA said many users were crushing up and injecting the painkiller to abuse it, according to NBC News.

“Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market,” the FDA said in a statement issued on Thursday (June 8). “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.”

Endo acknowledged its drug could be used for the wrong reasons but pushed back at the notion that Opana ER should be completely removed from the market.

“While

Read more…